Clinical Trials Actively Recruiting Patients With Ewing Sarcoma

Get Permission

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with Ewing sarcoma. The trials are investigating allogeneic stem cell transplantation, combination chemotherapies, immunotherapies, natural killer cells, adding agents to traditional treatment regimens, and more. All of the studies are listed on the National Institutes of Health website at

Phase I

Study Title: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy-Refractory Ewing Sarcoma

Study Type: Interventional/nonrandomized/single-group assignment

Study Sponsor and Collaborators: University of Louisville

Purpose: To examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory Ewing sarcoma

Primary Outcome Measures: Development of grade 3-4 graft vs host disease [time frame: 12 months]

Principal Investigator: Kenneth Lucas, MD, University of Louisville; 502-852-8450, Identifier: NCT01969942

Study Title: Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing’s Sarcoma Following Failure of Prior Chemotherapy

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: Massachusetts General Hospital

Purpose: To find the highest dose of the combination of olaparib and temozolomide that can be given safely to patients with Ewing sarcoma and to collect information about the effects of the combination on Ewing sarcoma

Primary Outcome Measures: Determine maximum tolerated dose of olaparib and temozolomide [time frame: 2 years]

Principal Investigator: Edwin Choy, MD, Massachusetts General Hospital; contact Barbara Anderson, RN, 617-643-2427, Identifier: NCT01858168

Study Title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor Niraparib and Temozolomide in Patients With Previously Treated, Incurable ­Ewing Sarcoma

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: Sarcoma Alliance for Research Through Collaboration

Purpose: To define the dose-limiting toxicities and maximum tolerated dose of the poly ADP-ribose polymerase inhibitor niraparib and escalating doses of temozolomide in patients with pretreated incurable Ewing sarcoma

Primary Outcome Measures: Dose-limiting toxicity and maximum tolerated dose [time frame: approximately 24 months]

Principal Investigator: Multiple locations; contact Sarcoma Alliance Office at 734-930-7600, Identifier: NCT02044120

Phase II

Study Title: A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High-Dose Alkylator-Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Study Type: Interventional/nonrandomized/parallel assignment

Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center

Purpose: To study what effects adding the combination of irinotecan and temozolomide to the standard EFT chemotherapy regimen has on Ewing sarcoma

Primary Outcome Measures: Event-free survival of patients with localized disease [time frame: 4 years]

Principal Investigator: Heather Magnan, MD, Memorial Sloan Kettering Cancer Center; 212-639-7937 Identifier: NCT01864109

Study Title: Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic ­Ewing Sarcoma

Study Type: Interventional/randomized/parallel assignment

Study Sponsor and Collaborators: National Cancer Institute

Purpose: To study how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed, metastatic ­Ewing sarcoma

Primary Outcome Measures: Time to adverse analytic event, defined to be disease-related event, diagnosis of a second malignant neoplasm, or death [time frame: from the time of randomization, assessed up to 5 years]

Principal Investigator: Steven ­DuBois, MD, Children’s Oncology Group; 255 study locations, see for each institution’s contact Identifier: NCT02306161

Study Title: Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial

Study Type: Interventional/single-group assignment

Study Sponsor and Collaborators: Medical College of Wisconsin

Purpose: To study how well cellular and adoptive immunotherapy using human leukocyte antigen-haploidentical hematopoietic cell transplantation followed by an early, post-transplant infusion of donor natural killer cells on Day +7 is tolerated in this heavily treated population

Primary Outcome Measures: Disease-control rate [time frame: 6 months]

Principal Investigator: Monica Thakar, MD, Medical College of Wisconsin; contact Shelly LeVeque, RN, BSN, 414-266-6471,; or Adam Fiebelkorn, CCRP, MS, 414-266-2137, Identifier: NCT02100891

Study Title: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

Study Type: Interventional/randomized/crossover assignment

Study Sponsor and Collaborators: Sarcoma Alliance for Research through Collaboration

Purpose: Although regorafenib was approved for use in patients who had progressive gastrointestinal stromal tumor despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma. This study looks to examine its effects on multiple sarcomas.

Primary Outcome Measures: Progression-free survival (Ewing/Ewing-like sarcoma) [time frame: up to 16 weeks]

Principal Investigator: Robert Maki, MD, PhD, Tisch Cancer Institute Mount Sinai Medical Center; contact Sarcoma Alliance Office, 734-930-7600, Identifier: NCT02048371 ■

Editor’s Note: The clinical trials presented here do not represent all the trials listed on For the complete list, go to